SBRC-Nottingham: Sustainable Routes to Platform Chemicals from C1 Wastes Gases

SBRC-Nottingham (www.sbrc-nottingham.ac.uk) was one of the first three UK university-based Synthetic Biology Research Centres (SBRCs) to be funded by the BBSRC and EPSRC as part of the recommendations made in the UK’s Synthetic Biology Roadmap. It was established in 2014 and builds on the pioneering work of the Clostridia Research Group (CRG) who have previously developed a range of gene tools for the modification of clostridial genomes [1-9].

Background to the CRG
Established in 2004, the CRG conducts research on biofuels [10-13], C. difficile infection and control [14-17], understanding the food pathogen C. botulinum [18-21] as well as developing therapeutic strategies for treating solid tumours [22-25]. The majority of this work has focussed on clostridia but the establishment of the SBRC-Nottingham has opened up the opportunity to a broader spectrum of bacteria and to now include aerobes, specifically Cupriavidus necator.

CRG Roadmap Technologies
The CRG have developed a series of technologies which when sequentially applied, have allowed the modification of new clostridial hosts. Several of the components of this ‘roadmap to gene system development’ are subject to patent protection: Synthetic Operon Construction in Clostridia Allele Coupled Exchange (ACE, WO 2009/101400); A negative / counter selection marker for use in clostridia: CodA selectable marker (WO2010/084349); Transposon delivery system for clostridia (vector) TraDis Transposon system (WO2013/144653); Orthogonal bacterial expression system (WO2013/144647); ClosTron (www.clostron.com) technology (WO/2007/148091). These technologies, along with the pMTL80000 modular vector series [1], are used to facilitate gene transfer and gene knock-out/knock-in and to generate bespoke chassis carrying genome inserted synthetic pathways and application specific modules.

SBRC Focus
Unlike many of the other UK SBRC’s the scope of the SBRC-Nottingham is highly directed and focuses on the conversion of waste C1 gases through bacterial fermentation to industrially useful hydrocarbon-based chemicals. The particular focus are those with multiple bonds (alkenes) such as s-hydroxypropionic acid, ethylene, propylene, isobutene, butadiene and isoprene. The molecules were chosen because of their industrial relevance, because they are ‘stepping off’ points for the production of more complex compounds using sustainable chemistry and because they are volatile, hence more easily recovered from the fermentation system which in turn helps prevent product levels accumulating to levels toxic to the bacteria.

The long-term aim of the SBRC-Nottingham is to break our reliance on fossil fuels as the source of the chemicals we use in our everyday lives and to make these chemicals sustainably using waste C1 whilst at the same time reducing C1 gas evolution to the atmosphere, hence reducing greenhouse gas emissions.

The SBRC-Nottingham is applying learning from the CRG to the Gram-negative bacterium Cupriavidis necator (formerly known as Ralstonia eutropha or Alcaligenes eutropha). This industrially relevant, facultatively chemolithoautotrophic bacterium is able to grow with organic substrates or H2 and CO2 under aerobic conditions. Under nutrient limitation, C. necator directs the majority of its reduced carbon flux into the synthesis of poly[(R)-3-hydroxybutyrate] (PHB), a biopolymer stored in intracellular granules. When cultivated with H2 and CO2, C. necator forms up to 61 g/liter of PHB in 48 h, representing about 70% of total cell weight [26]. Mutants defective in PHB production secrete large amounts of pyruvate into the growth medium when cultured chemolithoautotrophically, suggesting that these mutants maintain a comparable carbon flux in the presence or absence of PHB biosynthesis [27, 28].
Biosynthesis of PHB under nutrient-limiting conditions in *C. necator* has been industrially exploited in the production of biodegradable plastic for more than a decade (e.g., by ICI/Zeneca, Monsanto, and Metabolix). Only recently has *C. necator* been recognized as a candidate for biofuel production from CO$_2$, potentially producing carbon-neutral biofuels from nonphotosynthetic sources. Li and co-workers engineered a *C. necator* strain for electromicrobial conversion of CO$_2$ to C$_4$ and C$_5$ alcohols [29]. In their system, electricity powered the electrochemical reduction of CO$_2$ at a cathode to produce formate, which was then converted to isobutanol and 3-methyl-1-butanol by an engineered *C. necator* strain. With such a capacity to synthesise and store fixed carbon from CO$_2$, *C. necator* offers the promise of a chassis which through synthetic biology approaches will be able to synthesise and store other, industrially important platform chemicals.

**Inter-disciplinarity**

Synthetic biology is inherently multidisciplinary and the Centre’s academic leadership team membership is drawn from faculties and schools across the university including Chemistry, Life Sciences, Mathematics, Computer Science, Engineering, Social Sciences, Pharmacy and Biosciences. To create a coherent research community the SBRC - Nottingham has been provided with a dedicated floor in the University’s flagship Biomolecular Sciences research building on the University Park campus. This is a £40 million multidisciplinary research facility which also houses other multi-disciplinary teams. Researchers within the SBRC-Nottingham are co-located, in particular ‘lab-based’ scientists and mathematical modellers work in multidisciplinary teams. The SBRC-Nottingham is located within the science and engineering hub of the university with mechanisms in place for researchers based on other Campuses to spend dedicated time within the team. The SBRC-Nottingham positions Responsible Research and Innovation central to its activities with social scientists physically based within the SBRC to maximise interaction with synthetic scientists. There is a strong Outreach ethos with many links between the SBRC-Nottingham, local schools, Café Scientifique, Pub PhD, the media and other UK SBRCs. Many of these activities are undertaken in partnership with C1net (www.c1net.co.uk), a BBSRC Network in Industrial Biotechnology and Bioenergy (NIBB) coordinated from Nottingham.

**Equipment and facilities**

The SBRC-Nottingham has a wealth of dedicated new equipment, including flow cytometry, lab-scale fermentation facilities, analytics including HPLC, GC, MS, Raman spectroscopy as well as near- and mid-IR spectroscopy. A robotics suite is being established with bespoke systems able to carry out automated gene assembly, transformations, culturing and clone selection. The fermentation systems are of particular note. A gas-fermentation laboratory was first established in 2013 to explore anaerobic gas fermentation. Building on the knowledge gained from this facility, a new laboratory suite dedicated to anaerobic and aerobic gas fermentation for the SBRC has been commissioned and when fully operational will comprise over 20 gas-enabled Controlled Stirred Tank Reactors (CSTRs) as well as a gas-enabled RoboLector®, bench top micro fermentation system that allows high-throughput 48 X 2 ml fermentations together with online monitoring. These facilities are amongst the few available in the UK which have the capability to ferment waste C1 gases into fixed carbon from microbes. Although the facility operates only at lab-scale the new knowledge being generated will critically inform demonstrator and scale-up fermentation research. We are linking up with the Centre for Process Innovation on Teesside, UK to establish best practice in gas fermentation and gas safety in the UK and to share experience so that lab-scale fermentation knowledge more readily integrates with scale-up to larger plant.

**Training**

The University has a BBSRC Doctoral Training Programme which annually recruits 50 students, or which a third are targeted for Industrial Biotechnology, an University funded SBRC Synthetic Biology Doctoral Training Programme with 25 studentships to be
recruited over the 5-year funding lifetime of the SBRC and an EPSRC Doctoral Training Centre in Sustainable Chemistry which will recruit 60 students over the same time period. Together, these programmes are training the next generation of multi-disciplinary scientists in Synthetic Biology and related areas of science.

**Industrialisation and Application**

SBRC-Nottingham is carrying out fundamental academic research to understand the physiology and metabolism of microbial chassis that could have industrial application. Key outputs of the centre are (i) knowledge of fermentation conditions and constraints (ii) metabolic models which have through iteration led to (iii) optimised production chassis. Many of these outputs will be of interest to industry either directly or to inform industry’s processes which are developing in parallel. Translation to industry and the wider academic community is further facilitated through the activities of the Nottingham-led NIBB, C1net (www.c1net.co.uk).

Without compromising the SBRC-Nottingham’s academic interests and without constraining the widespread distribution of project outputs, we have teamed up with a newly formed synthetic biology company called CHAIN Biotechnology Ltd. This company provides one of the routes we are using to facilitate the wider adoption and also the exploitation of the outputs from the SBRC-Nottingham. This company has already taken responsibility for the distribution of SBRC background IP. Through the University of Nottingham, over 250 MTAs have been put in place for the pMTL80000 modular vector series developed by the CRG [1]. CHAIN Biotechnology Ltd, will further expand the distribution of these materials and build a global community of users to maximise the wider impacts of SBRC-Nottingham research outputs. The pMTL80000 series is designed for use in clostridial chassis. Further series are under development for *Cupriavidus* (pMTL70000 series), *Geobacillus* (pMTL60000 series) and for methylotrophs (pMTL90000 series).

**References**

[1] Heap JT, Pennington OJ, Cartman ST, Minton NP (2009) A modular system for *Clostridium* shuttle plasmids. *J. Microbiol. Methods* **78**:79-85.

[2] Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP (2010). The ClosTron: mutagenesis in *Clostridium*: refined and streamlined. *J. Microbiol. Methods*. **80**:49-55.

[3] Cartman ST, Minton NP (2010). A mariner-based transposon system for *in vivo* random mutagenesis of *Clostridium difficile*. *Appl. Environ. Microbiol.* **76**: 1103-1109.

[4] Cartman ST, Kelly ML, Heeg D, Heap JT, Minton NP (2012). Precise manipulation of the *Clostridium difficile* chromosome reveals a lack of association between tcdC genotype and toxin production. *Appl. Environ. Microbiol.* **78**: 4683-90.

[5] Kuehne SA, Minton NP (2012). ClosTron-mediated engineering of *Clostridium*. *Bioengineered* **3**: 1-8.

[6] Heap JT, Ehsaan M, Cooksley CM, Ng Y-K, Cartman ST, Winzer K, Minton NP (2012). Integration of DNA into bacterial chromosomes from plasmids without a counter-selection marker. *Nucl. Acids Res.* **40**:e59.

[7] Zhang Y, Grosse-Honebrink A, Minton NP (2015). A universal mariner transposon system for forward genetic studies in the genus *Clostridium*. *PLoS One*. **10**:e0122411.

[8] Ng YK, Ehsaan M, Philip S, Janoir C, Heap JT, Collignon A, Cartman ST, Minton NP. Expanding the repertoire of gene tools for precise manipulation of the
*Clostridium difficile* genome: allelic exchange using PyrE alleles. PLoS One 2013; 8(2):e56051.

[9] Ehsaan M, Kuit W, Zhang Y, Cartman ST, Heap JT, Winzer K, Minton NP (2016) Mutant generation by allelic exchange and genome resequencing of the biobutanol organism *Clostridium acetobutylicum* ATCC 824. Biotechnol. Biofuels 2016;9:4.

[10] Steiner E, Dago AE, Young DI, Heap JT, Minton NP, Hoch JA, Young M (2011) Multiple orphan histidine kinases interact directly with Spo0A to control the initiation of endospore formation in *Clostridium acetobutylicum*. Mol. Microbiol. 80: 641-54.

[11] Kuit W, Minton NP, López-Contreras AM, Eggink G (2012) Disruption of the acetate kinase (*ack*) gene of *Clostridium acetobutylicum* results in delayed acetate production. Appl Microbiol Biotechnol 94(3): 729-41.

[12] Cooksley CM, Zhang Y, Wang H, Redl S, Winzer K, Minton NP (2012). Targeted mutagenesis of the *Clostridium acetobutylicum* acetone-butanol-ethanol fermentation pathway. Metab. Eng. 14(6): 630-41

[13] Kovács K, Willson BJ, Schwarz K, Heap JT, Jackson A, Bolam DN, Winzer K, Minton NP (2013). Secretion and assembly of functional mini-cellulosomes from synthetic chromosomal operons in *Clostridium acetobutylicum* ATCC 824. Biotechnol. Biofuel. 6(1):117.

[14] Baban ST, Kuehne SA, Barketi-Klai A, Cartman ST, Kelly ML, Hardie KR, Kansau I, Collignon A, Minton NP (2013). The role of flagella in *Clostridium difficile* pathogenesis: comparison between a non-epidemic and an epidemic strain. PLoS One; 8(9):e73026.

[15] Kuehne SA, Collery MM, Kelly ML, Cartman ST, Cockayne A, Minton NP (2014). The importance of toxin A, toxin B and CDT in virulence of an epidemic *Clostridium difficile* strain. J. Infect. Dis. 209:83-6.

[16] Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A and Minton NP (2010). The role of toxin A and toxin B in *Clostridium difficile* infection. Nature 467: 711-713.

[17] Burns DA, Heap JT, Minton NP (2010) *Clostridium difficile* spore generation: an update. Res Microbiol. 161(9): 730-4.

[18] Nioche P, Berka V, Vipond J, Minton N, Tsai AL, Raman CS (2004) Femtomolar Sensitivity of a NO Sensor from *Clostridium botulinum*. Science 306:1550-1553.

[19] Cooksley CM, Davis IJ, Winzer K, Chan WC, Peck MW, Minton NP (2010) Regulation of neurotoxin production and sporulation by a putative agrBD signaling system in proteolytic *Clostridium botulinum*. Appl. Environ. Microbiol. 76: 4448-4460.

[20] Zhang Z, Korkea A, Dahlsten E, Sahala E, Heap JT, Minton NP, Lindström M (2013). Two-component signal transduction system CBO0787/CBO0786 represses transcription from botulinum neurotoxin promoters in *Clostridium botulinum* ATCC 3502. PLoS Pathogenesis 9(3):e1003252.

[21] Meaney CA, Cartman ST, McClure PJ, Minton NP (2016). The role of small acid-soluble proteins (SASPs) in protection of spores of *Clostridium botulinum* against nitrous acid. Int. J. Food. Microbiol. 216: 25-30.

[22] Liu S-C, Minton NP, Giaccia AJ and Brown JM (2002) Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumour hypoxia/necrosis. Gene Therapy 9: 291-296.

[23] Minton NP (2003) Clostridia in cancer therapy. Nature Microbiol Revs 1: 237-242.
[24] Theys J, Pennington O, Dubois L, Anlezark G, Vaughan T, Mengesha A, Landuyt W, Anné J, Burke PJ, Dürre P, Wouters BG, Minton NP and Lambin P (2006). Repeated cycles of *Clostridium*-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. *British J. Cancer 95*: 1212-9.

[25] Heap JT, Theys J, Ehsaan M, Kubiak A, Dubois L, Paesmans K, Van Mellaert L, Knox R, Kuehne SA, Lambin P and Minton NP (2014). Spores of *Clostridium* engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. *OncoTarget 5*: 1761-9.

[26] Ishizaki A, Tanaka K, Taga N (2001) Microbial production of poly-d-3-hydroxybutyrate from CO₂. *Appl. Microbiol. Biotechnol. 57*: 6–12.

[27] Cook A, Schlegel H (1978) Metabolite concentrations in *Alcaligenes eutrophus* H16 and a mutant defective in poly-β-hydroxybutyrate synthesis. *Arch. Microbiol. 119*: 231–235.

[28] Steinbüchel A, Schlegel HG (1989) Excretion of pyruvate by mutants of *Alcaligenes eutrophus*, which are impaired in the accumulation of poly(β-hydroxybutyric acid) (PHB), under conditions permitting synthesis of PHB. *Appl. Microbiol. Biotechnol. 31*: 168–175.

[29] Li H, Opgenorth PH, Wernick DG, Rogers S, Wu TY, Higashide W, Malati P, Huo YX, Cho KM, Liao JC (2012) Integrated electromicrobial conversion of CO₂ to higher alcohols. *Science 335*: 1596.